What's Going On With MannKind Stock?
Portfolio Pulse from Erica Kollmann
MannKind Corporation (NASDAQ:MNKD) shares are in focus due to initial meal challenge data from INHALE-3, a Phase 4 clinical trial for inhaled insulin, showing promising results. The company also reported Q4 earnings of 2 cents per share with sales of $58.47 million, surpassing analyst estimates. CNBC's Jim Cramer discussed the stock, noting its potential for an earnings breakout. Analysts have a 12-month price target range of $6.50 to $7.50, with an average of $7.00. MannKind shares are currently down 8.35% at $4.82.
March 11, 2024 | 2:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MannKind Corporation reported promising INHALE-3 trial results and Q4 earnings that beat estimates, with analysts setting a 12-month price target range of $6.50 to $7.50.
The positive results from the INHALE-3 trial and the Q4 earnings beat are significant developments for MannKind, likely to boost investor confidence and potentially drive the stock price up in the short term. Analysts' positive ratings and the upward price target suggest a bullish outlook for the stock.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100